Clinical Trials

201209135

A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer Phase II Principal Investigator Ma, Cynthia Disease Site Breast Learn more about this study…

201301106

A Phase II Trial of Neoadjuvant PD 0332991, a Cyclin-Dependent Kinase (Cdk) 4/6 inhibitor, in Combination with Anastrozole in Women with Clinical Stage 2 or 3 Estrogen Receptor Positive and HER2 Negative Breast Cancer Phase…

201312055

NSABP B-51/Endorsed Study: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy who Convert to Pathologically Negative…

201404107

A Co-clinical Trial in Triple Negative Breast Cancer Patients with Genoproteomic Discovery Phase II Principal Investigator Ademuyiwa, Foluso Disease Site Breast Learn more about this study at: clinicaltrials.gov

201405031

An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations Phase II Principal Investigator Park, Haeseong Disease Site Brain and Nervous System; Lung Learn more about this…

201407100

A PHASE 1B CLINICAL TRIAL TO EVALUATE THE SAFETY AND IMMUNE RESPONSE TO A MAMMAGLOBIN-A DNA VACCINE IN ER+, HER2- BREAST CANCER PATIENTS UNDERGOING NEOADJUVANT ENDOCRINE THERAPY OR CHEMOTHERAPY Phase I Principal Investigator Gillanders, William…

201502063

An Open-Label Study to Characterize the Incidence and Severity of Diarrhea in Patients with Early-Stage HER2+ Breast Cancer Treated with Neratinib and Loperamide

201503010

A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

201604023

PRAGMATIC PHASE III RANDOMIZED TRIAL OF PROTON VS. PHOTON THERAPY FOR PATIENTS WITH NON-METASTATIC BREAST CANCER RECEIVING COMPREHENSIVE NODAL RADIATION: A RADIOTHERAPY COMPARATIVE EFFECTIVENESS (RADCOMP) CONSORTIUM TRIAL Phase III Principal Investigator Zoberi, Imran Disease Site…

201607134

Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Phase III Principal Investigator Peterson, Lindsay Disease Site Breast Learn more about this…

201610019

A Phase II Neoadjuvant Study of Palbociclib in Combination with Letrozole and Trastuzumab as Neoadjuvant Treatment of Stage II-III ER+ HER2+ Breast Cancer (PALTAN) Phase II Priniciple Investigator Ademuyiwa, Foluso Disease Site Breast Learn more…

201610067

Prospective evaluation of high-dose (8 g/m2) systemic methotrexate in patients with breast cancer and leptomeningeal metastasis Phase II (Cancer Control) Principal Investigator Campian, Jian Disease Site Breast Learn more about this study at: clinicaltrials.gov

201611010

Endocrine Treatment Alone as Primary Treatment for Elderly Patients with Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score Phase II Principal Investigator Aft, Rebecca Disease Site Breast Learn more about this study at:…

201612071

A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Phase III Principal Investigator Peterson, Lindsay Disease Site Breast Learn more about this…

201701042

A Phase II Open-Label,Randomized Study of PARP inhibition (olaparib) Either Alone or in Combination with Anti-PD-LI Therapy (atezolizumab;MPDL3280A) in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC) Phase II Principal Investigator Park, Haeseong…

201704073

[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer (EAI142)

201710109

A Randomized Phase 1 Trial of Neoantigen DNA Vaccine Alone vs. Neoantigen Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Phase I Principal Investigator Gillanders, William Disease Site Breast…

201710148

A Multi-Center, Open-Label, Phase 1/1b Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anticancer Activity of Fruquintinib in Patients with Advanced Solid Tumors Phase I Principal Investigator Park, Haeseong Disease Site Anus; Brain and…

201802187

Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Radiation with Breast Reconstruction Phase III Principal Investigator Zoberi, Imran Disease Site Breast Learn more about this study at: clinicaltrials.gov

201808046

Evaluation of Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma Phase I/II Principal Investigator Zoberi, Imran Disease Site Breast Learn more about…

201810055

A Phase Ia/b Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of BTRC4017A Administered Intravenously as a Single Agent and in Combination with Trastuzumab in Patients with Locally Advanced or Metastatic Her2-Expressing Cancers Phase I…

201811109

A PHASE 3, MULTICENTER, RANDOMIZED,OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF DS-8201A, AN ANTI-HER2-ANTIBODY DRUG CONJUGATE, VERSUS TREATMENT OF INVESTIGATOR’S CHOICE FOR HER2-POSITIVE, UNRESECTABLE AND/OR METASTATIC BREAST CANCER SUBJECTS PRETREATED WITH PRIOR STANDARD OF CARE HER2 THERAPIES,INCLUDING T-DM1

201812035

RNA Disruption Assay (RDA) – Breast cancer Response EValuation for Individualized TherapY (BREVITY)

201902108

A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative…

201903188

Phase III placebo-controlled trial to evaluate dexamethasone use for everolimus-induced oral stomatitis: prevention versus early treatment approaches Phase III Principal Investigator Trikalinos, Nikolaos Disease Site Anus; Colon; Esophagus; Liver; Other Digestive Organ; Pancreas; Rectum; Small…

201904141

A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy Phase III Principal Investigator Ademuyiwa, Foluso Disease Site Breast Learn more about…

201905026

Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY) Phase N/A Principal Investigator Haroutounian, Simon Disease Site Breast; Hodgkin’s Lymphoma; Non-Hodgkin’s Lymphoma Learn more about this study at: clinicaltrials.gov

201905076

An Open-label, Randomized, Multicenter Study Evaluating the Activity of Lasofoxifene Relative to Fulvestrant for the Treatment of Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2-Breast Cancer with an ESR1 Mutation Phase II Principal Investigator Bagegni,…

201905083

Mammaprint, BluePrint and Full genome Data Linked with Clinical Data to Evaluate New Gene Expression Profiles: An Adaptable Registry (FLEX Registry) Phase N/A Principal Investigator Ma, Cynthia Disease Site Breast Learn more about this study…

201906022

A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Phase III Principal Investigator Frith, Ashley Disease Site Breast Learn more about this study at: clinicaltrials.gov

201906083

Phase 3 Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician’s Choice (TPC) in subjects with Hormonal Receptor-Positive (HR+) Human Epidermal Growth Factor Receptor 2 (HER2) Negative Metastatic Breast Cancer (MBC) who have failed at…

201907091

BYLieve: A phase II, multicenter, open-label, three-cohort, non-comparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2- negative advanced breast cancer…

201907095

A Phase 1/2, First-in-Human, Open-label, Dose Escalation Study of GB1275 Monotherapy and in Combination with an Anti-PD-1 Antibody in Patients with Specified Advanced Solid Tumors or in Combination with Standard of Care in Patients with…

201908045

OPEN-LABEL,MULTICENTRE, PHASE IB DOSE-ESCALATION STUDY OF MEN1611, A PI3K INHIBITOR COMBINED WITH TRASTUZUMAB ± FULVESTRANT, IN SUBJECTS WITH PIK3CA MUTATED HER2-POSITIVE LOCALLY RECURRENT UNRESECTABLE (ADVANCED) OR METASTATIC (A/M) BREAST CANCER PROGRESSED TO ANTI-HER2 BASED THERAPY…

201908073

Randomized, double-blind, phase 3 of tucatinib or placebo in combination with ado-trastuzumab emtansine (T-DM1) for subjects with unresectable locally advanced or metastatic HER2+ breast cancer Phase III Principal Investigator Frith, Ashley Disease Site Breast Learn…

201908111

A Phase 1 Multi-targeted Study to Promote Anti-Tumor Immunity in ER positive, Her2 Negative Advanced Breast Cancer Phase I Principal Investigator Hernandez Aya, Leonel Disease Site Breast Learn more about this study at: clinicaltrials.gov

201909214

Prospective validation trial of taxane therapy (docetaxel or weekly paclitaxel) and risk of chemotherapy induced peripheral neuropathy in African American women Phase II Principal Investigator Rearden, Timothy Disease Site Breast Learn more about this study…

201911047

Phase IB Pilot Study of Epicutaneous Cryoimmunotherapy Combined with Pembrolizumab for Cutaneous Metastatic Breast Cancer Phase I Principal Investigator Hernandez Aya, Leonel Disease Site Breast; Metastatic Disease Learn more about this study at: clinicaltrials.gov

201911082

A randomized Phase I/II trial of fulvestrant and abemaciclib in combination with copanlisib (FAC) versus fulvestrant and abemaciclib alone (FA) for endocrine-resistant, hormone receptor positive, HER2 negative metastatic breast cancer (FAC vs FA) Phase I/II…

202001160

A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors Phase I (Cancer Control) Principal Investigator Govindan, Ramaswamy Disease Site…

202003106

EA1181 (CompassHER2-pCR): Preoperative THP and postoperative HP in patients who achieve a pathologic complete response Part 1 Component of: The CompassHER2 Trials (COMprehensive use of Pathologic response ASSessment to optimize therapy in HER2-positive breast cancer)…

202004058

A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel – BRACELET-1 Study Phase II Principal Investigator…

202005073

A Phase 1 Multicenter Global First in Human Study of the CD73 Inhibitor LY3475070 as Monotherapy or in Combination with Pembrolizumab in Patients with Advanced Solid Malignancies Phase I Principal Investigator Opyrchal, Mateusz Disease Site…

202006070

A Phase III Double-blind Randomised Study Assessing the Efficacy and Safety of Capivasertib + Fulvestrant Versus Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic Hormone Receptor Positive, Human Epidermal Growth Factor Receptor…